Company: PHAT
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034183
Chunk: 87

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 16
Chunk 87
---

    (135
    )

    (1,634
    )

    Cash flows from financing activities

    Proceeds from issuance of common stock from exercise of stock options

    1,599

    124

    Net proceeds from issuance of debt

    59,400

    39,318

    Net proceeds from underwritten public offering

    121,775

    141,390

    Net proceeds from revenue interest financing transaction

    —

    172,675

    Net proceeds from issuance of common stock under ATM facility

    —

    14,073

    Net cash provided by financing activities

    182,774

    367,580

    Net (decrease) increase in cash and cash equivalents and restricted cash

    (84,131
    )

    228,366

    Cash and cash equivalents and restricted cash – beginning of period

    384,256

    155,890

    Cash and cash equivalents and restricted cash – end of period
     
    $
    300,125

    $
    384,256

    Supplemental disclosure of cash flow information

    Interest paid
     
    $
    17,293

    $
    11,133

    Supplemental disclosure of noncash investing and financing activities:

    Property and equipment purchases included in accounts payable and accrued expenses
     
    $
    8

    $
    18

    Final interest payment fee
     
    $
    1,800

    $
    2,200

    Settlement of ESPP liability in common stock
     
    $
    2,401

    $
    1,417

    Settlement of 401(k) liability in common stock
     
    $
    3,683

    $
    1,612

See accompanying notes.

F-7

PHATHOM PHARMACEUTICALS, INC.

Notes to Financial Statements

1. Organization, Basis of Presentation and Summary of Significant Accounting Policies Organization and Basis of Presentation Phathom Pharmaceuticals, Inc., or the Company or Phathom, was incorporated in the state of Delaware in January 2018. The Company is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The Company’s financial statements are prepared in accordance with U.S. generally accepted accounting principles, or GAAP.   On October 27, 2023, the U.S. Food and Drug Administration